All In Biotech

Drug Trial Radar · NCT03715153

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder. A 6-month Randomised, Double-blind, Placebo Controlled Multicentre Parallel Group Study to Evaluate Efficacy and Safety of Bumetanide 0.5mg Twice a Day Followed by an Open Label Active 6-month Treatment Period With Bumetanide (0.5mg Twice a Day) and a 6 Weeks Discontinuation Period After Treatment Stop.

Last checked: Nov 20, 2026Latest source record: Jun 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 211 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

211

Actual

Start

Oct 4, 2018

Primary completion

Oct 26, 2021

Study completion Oct 26, 2021

Sponsor

Lead sponsor
Institut de Recherches Internationales ServierAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ADIR, a Servier Group company
First posted
Oct 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the efficacity and the safety of bumetanide/S95008 in the improvement of Autism Spectrum Disorder core symptoms.

Conditions

  • Autism Spectrum Disorder (ASD)

Interventions

  • BUMETANIDE (S95008) for week 0 - 26Drug

    Oral solution dosed at 0.5 mg/mL Taken twice daily.

  • PLACEBO for week 0 - 26Drug

    Oral solution Taken twice daily.

  • Open-Label BUMETANIDE (S95008) for weeks 26 - 52Drug

    Oral solution dosed at 0.5 mg/mL Taken twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Childhood Autism Rating Scale, Second Edition (CARS2) Total Raw ScoreTime frame: Change from baseline to Week 26

Locations

50 sites in 12 countries. Site status is shown where the registry gives one.

  • Richmond Behavioral Associates

    Staten Island, New York

  • Liverpool Hospital

    Liverpool, Australia

  • The Royal Children's Hospital Melbourne

    Parkville, Australia

  • Trial Tech em Pesquisas com Medicamentos Ltda

    Curitiba, Brazil

  • Hospital Universitário Walter Cantídio-Universidade Federal do Ceará

    Fortaleza, Brazil

  • Clínica Neurológica e Neurocirúrgica de Joinville

    Joinville, Brazil

  • Hospital São Vicente de Paulo

    Passo Fundo, Brazil

  • Universidade Federal de São Paulo, Escola Paulista de Medicina

    São Paulo, Brazil

  • Faculdade de Medicina da Universidade de São Paulo - Departamento de psiquiatra

    São Paulo, Brazil

  • University Hospital Brno, Department of Child Neurology

    Brno, Czechia

  • Institute of Neuropsychiatric Care, Department of Child Psychiatry

    Prague, Czechia

  • University hospital of Ostrava, Department of Psychiatry

    Poruba, Ostrava, Czechia

  • GSC CHU-LENVAL Centre ressource autisme

    Nice, Alpes-Maritimes, France

  • Centre d'Investigation Clinique de Lyon

    Bron, Auvergne-Rhône-Alpes, France

  • Hôpital Le Vinatier CRA Rhône-Alpes, Bat 211

    Bron, Auvergne-Rhône-Alpes, France

  • Hôpitaux Universitaires de Strasbourg Service de Psychiatrie de l'Enfant et de l'Adolescent

    Strasbourg, Grand Est, France

  • Hôpital Robert Debré Service de Psychiatrie de l'enfant et de l'adolescent

    Paris, Île-de-France Region, France

  • Centre Hospitalier Charles Perrens CRA Aquitaine

    Bordeaux, New Aquitaine, France

  • Hôpital des Enfants-Pellegrin

    Bordeaux, New Aquitaine, France

  • CHU Rouen

    Rouen, Normandy, France

  • Centre Hospitalier du Rouvray Centre de Ressources pour l'Autisme

    Sotteville-lès-Rouen, Normandy, France

  • Vadaskert Korhaz es Szakambulancia

    Budapest, Hungary

  • Servus Salvus Kft.

    Budapest, Hungary

  • Magyar Református Egyház Bethesda Gyermekkórháza

    Budapest, Hungary

  • Bekes Megyei Kozponti Korhaz Gyermek es ifjusagpszichiatriai osztaly

    Gyula, Hungary

  • Szegedi Tudományegyetem Szent-Gyorgy Albert Klinikai Kozpont Gyermekgyógyászati Klinika Gyermek es Ifjusagpszichiátriai o

    Szeged, Hungary

  • Neuro Riabilitazione/Psicopatologia dell'età evolutiva Istituto Scientifico Medea - Bosisio Parini

    Bosisio Parini, Lombardy, Italy

  • U.O. di Neuropsichiatria Infantile Fondazione Istituto Neurologico Nazionale Casimiro Mondino Istituto di Ricovero e Cura a Carattere Scientifico

    Pavia, Lombardy, Italy

  • Clinica di Neuropsichiatria dell'Infanzia e dell'Adolescenza Ospedale Pediatrico-Microcitemico

    Cagliari, Sardinia, Italy

  • Programma Interdipartimentale "Autismo 0-90" A.O.U. Policlinico "Gaetano Martino"

    Messina, Sicily, Italy

  • U.O.C. Psichiatria dello Sviluppo IRCCS Fondazione Stella Maris

    Calambrone, Tuscany, Italy

  • U.O. di Neuropsichiatria Infantile Azienda Ospedaliera Universitaria Senese

    Siena, Tuscany, Italy

  • "Niepubliczny Zakład Opieki Zdrowotnej Gdańskie Centrum Zdrowia Sp. z o.o.

    Gdansk, Poland

  • Centrum Badań Klinicznych PI-House sp. z o.o

    Gdansk, Poland

  • NAVICULA Centrum Diagnozy i Terapii Autyzmu w Łodzi

    Lodz, Poland

  • Fundacja SYNAPSIS ul.

    Warsaw, Poland

  • Samodzielny Publiczny Dziecięcy Szpital Kliniczny w Warszawie Oddział Kliniczny Psychiatrii Wieku Rozwojowego

    Warsaw, Poland

  • Centro Hospitalar e Universitario de Coimbra Hospital Pediatrico

    Coimbra, Portugal

  • National Institute of Children Diseases, Department of Child Psychiatry

    Bratislava, Slovakia

  • EPAMED, s.r.o.

    Košice, Slovakia

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.